Head-To-Head Contrast: Vericel Corporation (VCEL) & Syros Pharmaceuticals (NASDAQ:SYRS)

Vericel Corporation (NASDAQ: VCEL) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitabiliy, institutional ownership, earnings, risk and analyst recommendations.

Risk and Volatility

Vericel Corporation has a beta of 3.1, meaning that its share price is 210% more volatile than the S&P 500. Comparatively, Syros Pharmaceuticals has a beta of -4.02, meaning that its share price is 502% less volatile than the S&P 500.

Profitability

This table compares Vericel Corporation and Syros Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vericel Corporation	-55.77%	N/A	-62.30%
Syros Pharmaceuticals	N/A	-112.47%	-58.87%

Institutional & Insider Ownership

31.9% of Vericel Corporation shares are owned by institutional investors. Comparatively, 49.5% of Syros Pharmaceuticals shares are owned by institutional investors. 3.3% of Vericel Corporation shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Vericel Corporation and Syros Pharmaceuticals’ revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	EBITDA	Earnings Per Share	Price/Earnings Ratio
Vericel Corporation	$49.64 million	2.05	-$22.39 million	($1.25)	-2.48
Syros Pharmaceuticals	$1.42 million	408.00	-$47.61 million	($7.03)	-3.15

Vericel Corporation has higher revenue and earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Vericel Corporation, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for Vericel Corporation and Syros Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel Corporation	0	0	3	0	3.00
Syros Pharmaceuticals	0	1	4	0	2.80

Vericel Corporation currently has a consensus target price of $6.00, suggesting a potential upside of 93.55%. Syros Pharmaceuticals has a consensus target price of $21.60, suggesting a potential downside of 2.39%. Given Vericel Corporation’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Vericel Corporation is more favorable than Syros Pharmaceuticals.

Summary

Vericel Corporation beats Syros Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

About Vericel Corporation

Vericel Corporation, formerly Aastrom Biosciences, Inc., is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment. Its autologous cell therapy products include Carticel (autologous cultured chondrocytes), which is an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), which is a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns. The Company is developing MACI, which is a third-generation autologous chondrocyte implant and ixmyelocel-T, which is a patient-specific multicellular therapy.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company’s drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, inflammatory diseases and other diseases to identify optimal points of therapeutic intervention in specific subsets of patients.